The people who deserve extra attention usually include: Patients with a known history of diabetic retinopathy Patients with diabetic macular edema Patients with recently worsening retinopathy Patients with poor baseline glucose control who may experience a large A1c drop Patients starting semaglutide while already under retina treatment Patients with multiple high-risk features such as kidney disease, hypertension, or long-standing diabetes In contrast, a patient with type 2 diabetes, no known retinopathy, and a recent normal dilated exam may still need routine follow-upbut often not the same level of concern as someone with active retinal disease
The starting dose considerations from your tirzepatide experience still inform your approach, but conservatism serves you well here
The licensing of compounding pharmacies is primarily managed at the state level by respective State Boards of Pharmacy
And it doesn't just happen with endometriosis care, it's happening with perimenopause
Read all patient information, medication guides, or drug information sheets that come with your medication